Early Detection Research Network

Lung

Levels of the four proteins (SLPI, TFPI, TFPI2, and TIMP1) were studied in a set of 12 late stage lung cancer serum samples and 12 normal serum samples using the immunoaffinity-MRM methodology. It was found that the immunoaffinity-mass spectrometry-based quantification approach provides a specific and accurate assay for verifying the expression of potential biomarkers in patient serum samples especially for those proteins for which the necessary reagents for ELISA development are unavailable. (From PMID:18388126)
http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/1077/1056
Under Review
One
Researchers have developed an immunoaffinity-mass spectrometry-based approach using antibodies to enrich multiple proteins of interest from sera followed by LC-MRM-based quantification. As a proof of concept, it was demonstrated that CEA can be detected and quantified in a subset of patient sera. This is the first reported detection of CEA in sera using a mass spectrometry-based approach in serum samples. This method has allowed quantifying potential protein biomarkers in sera in the low ng/ml range with an acceptable CV. This approach was further applied to potential protein biomarkers discovered from tumor cell lines and tumor tissues. A linear response was obtained from a multiplex spiking experiment in normal human sera for secretory leukocyte peptidase inhibitor (4-500 ng/ml), tissue factor pathway inhibitor (TFPI) (42-1000 ng/ml), tissue factor pathway inhibitor 2 (TFPI2) (2-250 ng/ml), and metalloproteinase inhibitor 1 (TIMP1) (430-1000 ng/ml). (From PMID:18388126)
a9495de036864d978e1d1db997eaeb6d
no
no
Contents

There are currently no items in this folder.